Breaking News

Elevation Oncology Expands Pipeline with CSPC Pharma ADC

Licenses of EO-3021, a clinical stage anti-claudin18.2 antibody drug conjugate with potential in gastrointestinal cancers and other solid tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Elevation Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision oncology products for genomically defined cancers, has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group, to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China. SYSA1801 is curren...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters